Medidata teams with Shyft to bring real-world evidence data to drug development


Medidata ($MDSO) has teamed up with Shyft Analytics to use real-world evidence (RWE) data to inform drug development strategies. The pact, which comes days after Medidata led a $12.5 million investment in Shyft, is focused on analyzing RWE data to improve trial design and site selection.

In recent years, Medidata has sought to leverage its own repositories of data to improve these and other areas of the clinical trial process. By hooking up with Shyft, the eClinical leader has opened a new front in this strategy.

Notably, while Medidata’s focus is on clinical trials, Shyft is more interested in what happens to drugs and patients in the real world, giving it access to analytic capabilities that could be complementary to those possessed by its new partner and investor. Medidata thinks now is the right time to start tapping into RWE data.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

“As life sciences companies embark on more complex and targeted programs in oncology, rare diseases and a range of therapeutic areas, embedding real world evidence data and outcomes-based analytics early in the clinical trial process is imperative for success,” Medidata COO Mike Capone said in a statement.

Through their joint offering, Medidata and Shyft want to help clients pick out patient populations that are eligible for the sort of “complex and targeted” therapeutic areas referred to by Capone. If successful, the offering will give companies a way to address perennial problem of enrolling patients in clinical trials. Medidata and Shyft also see the collaboration improving protocol designs.

Shyft unveiled the pact days after disclosing its Series B round. The round saw Medidata team up with the VC wing of McKesson ($MCK) to funnel $12.5 million in Shyft. For the Series B round, Shyft deliberately opted for strategic investors, a move that suggested it wanted more than just money from Medidata, something the release of details about the RWE pact has confirmed.

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.